Key facts
- Taienkang Bio’s last known valuation is $15.9M (May 2025).
- It has raised $7.7M; the latest was Seed Round ($7.7M) in May 2025.
- Status: Privately Held (backing).
- ·Watchlist + deal alerts for Taienkang Bio
- ·The full record, as it builds
Funding rounds
No funding rounds for Taienkang Bio are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Taienkang Bio
Developer of drugs designed for health. The company's products mainly focus on biopharmaceuticals, which include pharmaceutical production, pharmaceutical import and export, and pharmaceutical contract production, providing customers with reliable and innovative products.
- Sector
- Healthcare
- HQ
- Anshan, China
- Founded
- 2025
- Ownership
- Privately Held (backing)
Taienkang Bio doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Taienkang Bio shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Taienkang Bio in its N-PORT filings yet. We sweep new filings monthly.